News - Onyx Pharmaceuticals, Kyprolis


Popular Filters

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma


US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

Onyx soars as FDA approves Kyprolis for multiple myeloma


Shares of US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) leapt 11.7% to $76.38 on Friday, after…

BiotechnologyKyprolisNorth AmericaOncologyOnyx PharmaceuticalsRegulation

Batch of mixed opinions from FDA advisory panels


Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Back to top